media – Page 615 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

NHS to fund gene therapy for ‘bubble babies’

The NHS will fund gene therapy for the first time, with a £500,000 treatment for “bubble baby syndrome”.
- Source: Telegraph
- 1,049
- October 26, 2017
gene immune defiency Market Views NHS therapy
Diabetes–New compounds may lower blood sugar but prevent weight gain

Researchers are one step closer to a new drug that could lower blood glucose levels in patients with insulin resistance, but without the potentially harmful side effects.
- Source: medicalnewstoday
- 732
- October 26, 2017
blood glucose diabetes insulin Researches resistance
Blood thinners slash dementia risk in A-fib patients

New research published in the European Heart Journal suggests that blood-thinning drugs such as warfarin may protect not only against stroke, but also against dementia in people who have atrial fibrillation.
- Source: medicalnewstoday
- 601
- October 26, 2017
A-fib blood-thinning drugs Dementia Researches stroke
FDA warns UVLrx Therapeutics over clinical trial missteps

The FDA this week released a warning letter it sent to UVLrx Therapeutics over issues with an unapproved study of an intravascular catheter, citing failures to obtain approval for the trial alongside a number of other violations.
- Source: massdevice
- 787
- October 26, 2017
FDA intravascular catheter Market Views
How to turn damaged heart tissue back into healthy heart muscle—new details emerge

Now, in a new study published today in Nature, UNC researchers report a breakthrough. They have used single cell RNA sequencing technology in combination with mathematical modeling and genetic and chemical approaches to delineate the step-by-step molecular changes that occur during cell fate conversion from fibroblast to cardiomyocyte.
- Source: medicalxpres
- 579
- October 26, 2017
cardiology regenerative medicine
Alector and AbbVie Announce Collaboration to Advance a Novel Class of Immune Therapies for Patients with Alzheimer’s Disease

AbbVie (ABBV), a global biopharmaceutical company, and Alector, a privately owned biotechnology company, announced a global strategic collaboration to develop and commercialize medicines to treat Alzheimer's disease and other neurodegenerative disorders.
- Source: finance.yahoo
- 677
- October 26, 2017
AbbVie Alzheimer's disease Market Views
Abbott rolls out smartphone-connected ICM in the U.S.

The FDA has cleared Abbott’s smartphone-compatible insertable cardiac monitor (ICM), the first and only device of its kind in the U.S. This provides patients and physicians with another way to monitor and diagnose abnormal heart rhythms.
- Source: Guidedsolutions
- 593
- October 25, 2017
heart rhythms ICM New Approvals
New synthetic genetic tool measures and manipulates protein aggregation in live cells

A common thread ties seemingly unlinked disorders like Alzheimer's disease and type II diabetes together. This thread is known as protein aggregation and happens when proteins clump together. These complexes are a hallmark of many diseases, but have recently been linked to beneficial functions as well.
- Source: news-medical
- 398
- October 25, 2017
prions protein aggregation
Gemini Reels In $42M to Target Root Causes of Age-Related Blindness

One of the biggest risk factors for vision loss is age. As people grow old, the central part of the retina can become damaged, leading patients to lose the central part of their vision in a condition called age-related macular degeneration (AMD).
- Source: Xconom
- 401
- October 25, 2017
age-related macular degeneration Market Views
FDA Approves Once-Weekly Bydureon BCise (exenatide) for Patients with Type-2 Diabetes

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Bydureon® BCise™ (exenatide extended-release) injectable suspension, a new formulation of Bydureon (exenatide extended-release) injectable suspension in an improved once-weekly, single-dose autoinjector device for adults with type-2 diabetes whose blood sugar remains uncontrolled on one or more oral medicines in addition to diet and exercise, to improve glycemic control.
- Source: AstraZeneca
- 460
- October 25, 2017
Bydureon diabetes New Approvals

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.